马来酸依那普利/盐酸乐卡地平(Enalapril Maleate/Lercanidipine Hydrochloride) - 药物靶点：ACE x VDCCs_在研适应症：高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Atover、Carmen ACE、Coripren

+ [9]

靶点

ACE x VDCCs

作用方式

抑制剂、阻滞剂

作用机制

ACE抑制剂(血管紧张素转化酶抑制剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂)

治疗领域

心血管疾病

在研适应症

高血压

非在研适应症-

原研机构

Recordati SpA

在研机构

Viatris Pty Ltd.

Recordati SpA

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

澳大利亚 (2008-02-14),

高血压

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C36H42ClN3O6

InChIKeyWMFYOYKPJLRMJI-UHFFFAOYSA-N

CAS号132866-11-6

查看全部结构式(2)

关联

2

项与马来酸依那普利/盐酸乐卡地平相关的临床试验

NCT01211314

/ Terminated临床4期IIT

Treatment of Essential Hypertension With Vasodip-Combo 20. Efficacy and Safety Evaluation With 24 h Ambulatory Blood Pressure Measurements

Treatment and control of hypertension is still insufficient. About 50% of the patients remain uncontrolled. Lack of compliance with discontinuation of drug treatment is an important reason for not achieving blood pressure. Several studies have shown that use of fixed combinations improve compliance significantly, by reducing the number of pill's intake.
This study will assess the antihypertensive efficacy of Vasodip-Combo 20® [enalapril 20 mg + lercanidipine 10 mg] as a fixed combination drug in uncontrolled antihypertensive patients.

开始日期2011-01-01

申办/合作机构

Meir Medical Center

[+1]

NCT01093807

/ Completed临床2期

Randomized, Parallel Group, Double-blind Trial to Evaluate Different Dose Combinations of Lercanidipine and Enalapril in Comparison With Each Component Administered Alone and With Placebo in Patients With Essential Hypertension

The purpose of this study is to evaluate the efficacy and safety of various dosage combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with their respective components and with placebo.

开始日期2010-03-01

申办/合作机构-

100 项与马来酸依那普利/盐酸乐卡地平相关的临床结果

登录后查看更多信息

100 项与马来酸依那普利/盐酸乐卡地平相关的转化医学

登录后查看更多信息

100 项与马来酸依那普利/盐酸乐卡地平相关的专利（医药）

登录后查看更多信息

2

项与马来酸依那普利/盐酸乐卡地平相关的文献（医药）

2011-01-01·Cardiology Research

Does the Cardiologist Have a Key Role in Long-Term Management of Hypertension?

Article

作者: Steverding, Dietmar ; Wilke, Andreas

BACKGROUNDHypertension is a widespread chronic condition which is usually treated with hypertensive drugs. However, 50% of hypertensive patients do not achieve control of their blood pressure below the standard target of 140/90 mmHg when treated with a single antihypertensive drug. Generally, hypertension specialists have a key role in managing hypertensive patients.METHODSA retrospective case note review based on observations made in a cardiological outpatient clinic in Germany was carried out to assess whether the recommendation given by hypertension specialists were followed. The aim was to lower the blood pressure to < 130/85 mmHg over a period of six months by administering the new antihypertensive drug Zaneril^® (lercanidipine/enalapril). Twenty-four hour blood pressure profiles were monitored a fortnight and six months later.RESULTSOf the 130 patients, whose average blood pressure was 163/87 mmHg before receiving hypertensive treatment, only 44 (34%) were still on Zaneril^® therapy six months later. Eighty-four patients (65%) did not turn up for follow-up examinations. The blood pressure of patients who were under Zaneril^® therapy for the whole six months was better adjusted than that of patients who changed their treatment in the meantime (133/78 mmHg vs. 139/80 mmHg).CONCLUSIONSSpecialists have only little influence on the long-term therapy of hypertensive patients.

Arzneimittelforschung

Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension

Article

作者: Rump, Christian

The purpose of this first prospective observational cohort study after launch was to document the efficacy and tolerability of therapy with the fixed combination of lercanidipine HCl (CAS 132866-11-6), a third-generation calcium antagonist, and the angiotensin converting enzyme (ACE) inhibitor enalapril maleate (CAS 76095-16-4) in patients with essential hypertension in daily practice. Both parts of the observational study were conducted with the fixed combination of enalapril maleate 10 respectively 20 mg and lercanidipine HCl 10 mg, one part with Zaneril and the other with Zanipress. The fixed combination is marketed under these product names in Germany. The data of 8,440 patients with a mean age of 62 years and a mean body mass index (BMI) of 28 kg/m2 were evaluated. 84% of the patients had already received pre-treatment for essential hypertension. 26% of all the patients were known to have had hypertension for at least 10 years. Around 70% had further concomitant diseases. The mean blood pressure before the beginning of the study was 162.5/ 94.5 mmHg, the mean reduction after around three months was 28.4/ 13.5 mmHg. Just under 80% of the patients reached the desired target blood pressure after the observation period. The global assessment of the physicians shows that the efficacy of the drugs was "very good" to "good" for 94% of the patients. Global tolerability was assessed as "very good" and "good" for 97% of the patients. Compliance was stated as "very good" and "good" for 97% of the patients. Adverse drug reactions were documented for 2% of all patients.

100 项与马来酸依那普利/盐酸乐卡地平相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	C09BB02	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高血压	澳大利亚	Viatris Pty Ltd.	2008-02-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


[OP.LB03.07] (ESH2016)	N/A	高血压	56	Lercanidipine 10 mg/Enalapril 20 mg	艱襯齋餘積鏇窪鬱鑰範(獵鬱積獵網鬱襯鹽範鑰) = 齋積觸繭簾餘憲衊襯製廠構齋觸範簾觸齋遞鏇 (窪鹽積願願憲鏇簾簾廠, 27.1) 更多	积极	2016-09-01
				Amlodipine 5 mg/Enalapril 20 mg	鏇製糧鏇窪鹽獵艱製選(醖醖襯構顧壓簾繭蓋鬱) = 範糧願齋積壓壓顧壓衊壓襯廠襯網襯淵獵選網 (獵廠築鬱窪範廠壓觸範, 7.4)